ziconotide has been researched along with Hypotension--Orthostatic* in 2 studies
1 trial(s) available for ziconotide and Hypotension--Orthostatic
| Article | Year |
|---|---|
Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans.
SNX-111 is the first neuronal N-type, voltage-sensitive calcium channel (VSCC) blocker to enter clinical drug development. Areas of potential therapeutic utility include treatment of nociceptive and neuropathic pain and neuroprotection after ischemic brain injury. The data presented demonstrate that SNX-111 is biologically active in humans and indicate for the first time a neurophysiologic function of N-type VSCCs in humans. Topics: Adolescent; Adult; Blood Pressure; Calcium Channel Blockers; Heart Rate; Humans; Hypotension, Orthostatic; Injections, Intravenous; Male; omega-Conotoxins; Peptides | 1997 |
1 other study(ies) available for ziconotide and Hypotension--Orthostatic
| Article | Year |
|---|---|
Adverse effects associated with the intrathecal administration of ziconotide.
The omega-conopeptide, ziconotide, is an N-type calcium-channel blocker that has been shown to produce antinociception in animals using formalin and hot-plate tests. Initial reports of intrathecal administration of ziconotide in cancer and AIDS patients whose pain was unrelieved with opioids demonstrated analgesic efficacy. Although adverse effects were reported, these appeared to be easily managed through dose reduction or symptomatic treatment. This clinical report describes the experiences of three patients with serious adverse effects associated with intrathecal ziconotide. Topics: Ataxia; Back Pain; Calcium Channel Blockers; Confusion; Humans; Hypotension, Orthostatic; Injections, Spinal; Male; Middle Aged; Multiple Sclerosis; Nystagmus, Pathologic; omega-Conotoxins; Pain; Urinary Bladder Neoplasms | 2000 |